Edwards Lifesciences — Oct 30, 2025 release

The company is increasing its full-year EPS guidance and now expects adjusted EPS to be within the range of $2.56 to $2.62, versus previous guidance of the high end of $2.45 to $2.55. For the fourth quarter, the company projects total sales to be between $1.51 and $1.59 billion and adjusted EPS of $0.58 to $0.64. About Edwards Lifesciences      Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. 4 Conference Call and Webcast Information      The company will be hosting a conference call today at 2:00 p.m. PT to discuss its third quarter results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com or www.edwards.com. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “an